Skip to main content
November 18, 2020
Cannabis use disorder significantly raises the risk of medication noncompliance among inpatients with schizophrenia, according to a study published online in Schizophrenia Research.
November 10, 2020
A majority of inpatients with schizophrenia who were treated with electroconvulsive therapy (ECT) demonstrated clinical improvement, irrespective of whether they were capable of consenting before psychiatric treatment, a study found.
November 02, 2020
Janssen is seeking US Food and Drug Administration (FDA) approval for the first long-acting injectable (LAI) medication for schizophrenia that would be taken only twice a year.
October 13, 2020
Two advisory committees appointed by the US Food and Drug Administration (FDA) have voted in favor of ALKS 3831, a combination of olanzapine and the novel molecular entity samidorphan, Alkermes announced.
October 01, 2020
Deutetrabenazine offers long-term benefit for patients with severe tardive dyskinesia (TD), according to results from a 3-year open-label extension trial presented in a poster at Psych Congress 2020.
October 01, 2020
Adverse events in patients treated with deutetrabenazine were more common during titration than maintenance, a finding that provides “important context for the dosing schedule to providers and patients.”
September 11, 2020
Patients initiated on long-acting injectables for the treatment of schizophrenia had fewer hospitalizations and emergency department visits, compared with patients treated with oral antipsychotics, according to a poster presented at Psych Congress 2020. 
September 11, 2020
The metabolic profile of lumateperone 42 mg appears favorable, according to a post hoc analysis of a trio of studies involving patients with schizophrenia. Researchers shared their findings at Psych Congress 2020.
September 11, 2020
A 6-month extension of a published short-term trial showed continued improvement with SEP-363856 in patients with schizophrenia, researchers reported in a poster at Psych Congress 2020.
September 11, 2020
A large-scale analysis of insurance databases found a high prevalence of medical and psychiatric comorbidities among patients with schizophrenia, compared with matched controls, according to a poster presented at Psych Congress 2020.
Back to Top